TCGA-46-3767-01A-01R-0980-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 76
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.680
- ANGIOGENESIS+0.560
- TGF_BETA_SIGNALING+0.540
- UV_RESPONSE_DN+0.450
- INFLAMMATORY_RESPONSE+0.440
- KRAS_SIGNALING_UP+0.430
- ALLOGRAFT_REJECTION+0.410
- COMPLEMENT+0.400
- TNFA_SIGNALING_VIA_NFKB+0.380
- IL6_JAK_STAT3_SIGNALING+0.370
Top 10 suppressed
- MYC_TARGETS_V2-0.610
- E2F_TARGETS-0.440
- G2M_CHECKPOINT-0.360
- OXIDATIVE_PHOSPHORYLATION-0.350
- MYC_TARGETS_V1-0.310
- DNA_REPAIR-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.250
- INTERFERON_ALPHA_RESPONSE-0.240
- SPERMATOGENESIS-0.200
- CHOLESTEROL_HOMEOSTASIS-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | GSM6454738 | — | A | 0.934 |
| 2 | TCGA-E9-A1NG-01A-21R-A14M-07 | — | A | 0.921 |
| 3 | TCGA-BH-A1EO-01A-11R-A137-07 | — | A | 0.919 |
| 4 | TCGA-44-6774-01A-21R-1858-07 | — | cohortA1 | 0.912 |
| 5 | 20030015.LumB | — | A | 0.909 |
| 6 | TCGA-77-8008-01A-21R-2187-07 | — | cohortSQ1 | 0.907 |
| 7 | TCGA-K4-A4AB-01B-12R-A28M-07 | — | — | 0.905 |
| 8 | cdb7b56c-ddca-4596-bfa2-6823c12837e2 | — | — | 0.904 |
| 9 | c2ccc6b3-34d8-47c5-9367-cc53aad1622e | — | — | 0.901 |
| 10 | fd618c1b-e230-408d-aed8-4ad6df3fc4e6 | — | — | 0.898 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.680 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.560 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.540 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.450 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.430 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| COAGULATION | 0.360 | Binimetinib | — uncovered |
| HYPOXIA | 0.350 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.340 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.290 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |